Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;22(9):1562-9.
doi: 10.3201/eid2209.151579.

Prediction of Protection against Asian Enterovirus 71 Outbreak Strains by Cross-neutralizing Capacity of Serum from Dutch Donors, The Netherlands

Sabine M G van der Sanden, Gerrit Koen, Hetty van Eijk, Sylvie M Koekkoek, Menno D de Jong, Katja C Wolthers

Prediction of Protection against Asian Enterovirus 71 Outbreak Strains by Cross-neutralizing Capacity of Serum from Dutch Donors, The Netherlands

Sabine M G van der Sanden et al. Emerg Infect Dis. 2016 Sep.

Abstract

Outbreaks of human enterovirus 71 (EV-71) in Asia are related to high illness and death rates among children. To gain insight into the potential threat for the population of Europe, we determined the neutralizing activity in intravenous immunoglobulin (IVIg) batches and individual serum samples from donors in the Netherlands against EV-71 strains isolated in Europe and in Asia. All IVIg batches and 41%, 79%, and 65% of serum samples from children ≤5 years of age, women of childbearing age, and HIV-positive men, respectively, showed high neutralizing activity against a Dutch C1 strain, confirming widespread circulation of EV-71 in the Netherlands. Asian B3-4 and C4 strains were efficiently cross-neutralized, predicting possible protection against extensive circulation and associated outbreaks of those types in Europe. However, C2 and C5 strains that had few mutations in the capsid region consistently escaped neutralization, emphasizing the importance of monitoring antigenic diversity among circulating EV-71 strains.

Keywords: Asian enterovirus 71; Dutch; Europe; Picornaviruses; cross protection; cross-neutralization; enterovirus; human enterovirus 71; intravenous immunoglobulins; seroprevalence; the Netherlands; viruses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
EV-71 nAb titers in IVIg batches composed of plasma from Dutch (6 batches), Japanese (2 batches), and Vietnamese (1 batch) donors and in a polyclonal rabbit serum against EV-71 C1 91–480. nAb titers are presented as log2 values. EV-71, enterovirus 71; IVIg, intravenous immunoglobulin; nAb, neutralizing antibody; NL, the Netherlands.
Figure 2
Figure 2
Enterovirus 71 nAb titers in serum collected from Dutch children ≤5 years of age, women of childbearing age, and HIV-positive men during 2010–2014. nAb titers are presented as log2 values. Median titers (wide horizontal lines) with interquartile ranges (error bars) are indicated for each category. nAb, neutralizing antibody.
Figure 3
Figure 3
Enterovirus 71 nAb titers in serum collected from Dutch children (<0.5 years, 0.5–2 years and >2–5 years of age) during 2010–2014. nAb titers are presented as log2 values. Median titers (wide horizontal lines) with interquartile ranges (error bars) are indicated for each category. nAb, neutralizing antibody.
Figure 4
Figure 4
Amino acid sequence comparison of the capsid regions of EV-71 strains used for serologic analysis of strains isolated in Asia and Europe in study of immunity to these strains after exposure to IVIg from viruses from the Netherlands. Residues 164, 240, and 241 of VP1 (differing among genogroup B and C viruses and located in known antigenic sites) and residues that differ among neutralizable and nonneutralizable strains are marked by boxes. Known epitopes and antigenic determinants for EV-71 are marked in gray (22–25). EV-71, enterovirus 71; IVIg, intravenous immunoglobulin; VN, Vietnam; VP, viral protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe.
    Benschop KSM, Broberg EK, Hodcroft E, Schmitz D, Albert J, Baicus A, Bailly JL, Baldvinsdottir G, Berginc N, Blomqvist S, Böttcher S, Brytting M, Bujaki E, Cabrerizo M, Celma C, Cinek O, Claas ECJ, Cremer J, Dean J, Dembinski JL, Demchyshyna I, Diedrich S, Dudman S, Dunning J, Dyrdak R, Emmanouil M, Farkas A, De Gascun C, Fournier G, Georgieva I, Gonzalez-Sanz R, van Hooydonk-Elving J, Jääskeläinen AJ, Jancauskaite R, Keeren K, Fischer TK, Krokstad S, Nikolaeva-Glomb L, Novakova L, Midgley SE, Mirand A, Molenkamp R, Morley U, Mossong J, Muralyte S, Murk JL, Nguyen T, Nordbø SA, Österback R, Pas S, Pellegrinelli L, Pogka V, Prochazka B, Rainetova P, Van Ranst M, Roorda L, Schuffenecker I, Schuurman R, Stoyanova A, Templeton K, Verweij JJ, Voulgari-Kokota A, Vuorinen T, Wollants E, Wolthers KC, Zakikhany K, Neher R, Harvala H, Simmonds P. Benschop KSM, et al. Emerg Infect Dis. 2021 Jun;27(6):1616-1626. doi: 10.3201/eid2706.203096. Emerg Infect Dis. 2021. PMID: 34013874 Free PMC article.
  • Advances in anti-EV-A71 drug development research.
    Wang S, Pang Z, Fan H, Tong Y. Wang S, et al. J Adv Res. 2024 Feb;56:137-156. doi: 10.1016/j.jare.2023.03.007. Epub 2023 Mar 30. J Adv Res. 2024. PMID: 37001813 Free PMC article. Review.
  • Neutralising Antibodies against Enterovirus and Parechovirus in IVIG Reflect General Circulation: A Tool for Sero-Surveillance.
    Couderé K, van der Straten K, Brouwer L, Koen G, van Eijk H, Pajkrt D, Murk JL, Wolthers KC. Couderé K, et al. Viruses. 2021 May 29;13(6):1028. doi: 10.3390/v13061028. Viruses. 2021. PMID: 34072486 Free PMC article.
  • Phylogenetic characteristics and molecular epidemiological analysis of novel enterovirus EV-B83 isolated from Tibet, China.
    Xiao J, Zhang Y, Hong M, Han Z, Zhang M, Song Y, Yan D, Zhu S, Xu W. Xiao J, et al. Sci Rep. 2020 Apr 20;10(1):6630. doi: 10.1038/s41598-020-63691-4. Sci Rep. 2020. PMID: 32313119 Free PMC article.
  • Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019-2021.
    Lian H, Jiang H, Yi L, Sun J, Xie H, Qiu M, Sun L, Lin H, Yang M, Qu L, Yang H, Lu J, Zeng H. Lian H, et al. Biosaf Health. 2023 May 6;5(3):168-173. doi: 10.1016/j.bsheal.2023.05.002. eCollection 2023 Jun. Biosaf Health. 2023. PMID: 40078511 Free PMC article.
See all "Cited by" articles

References

    1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–90. 10.1016/S1473-3099(10)70194-8 - DOI - PubMed
    1. Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60:797–803. 10.1093/cid/ciu852 - DOI - PubMed
    1. Saxena VK, Sane S, Nadkarni SS, Sharma DK, Deshpande JM. Genetic diversity of enterovirus A71, India. Emerg Infect Dis. 2015;21:123–6. 10.3201/eid2101.140743 - DOI - PMC - PubMed
    1. Yu H, Chen W, Chang H, Tang R, Zhao J, Gan L, et al. Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes. 2010;41:1–4. 10.1007/s11262-010-0472-9 - DOI - PubMed
    1. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84:3339–50. 10.1128/JVI.01019-09 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources